Navigation Links
New opportunities for covalent drugs published by Avila scientists
Date:4/1/2011

WALTHAM, MA April 1, 2011 Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs" (www.nature.com/reviews/drugdisc, Vol. 10, April 2011, Singh, J.). This article discusses the broad opportunities for covalent drugs and how structural bioinformatics coupled with structure-based drug design can enable the design of highly selective covalent drugs with unique therapeutic properties for treating diseases.

"Many important and widely-used medicines work through a covalent mechanism of action," commented Juswinder Singh, PhD, Avila's Chief Scientific Officer and lead author on the publication. "Until recently, such covalent drugs were discovered by chance. However, today it is possible to design highly-specific covalent drugs by systematically applying rational drug design techniques and leveraging the vastly greater availability of structural information on disease targets. We anticipate the next few years will see an emergence of innovative covalent drugs that can solve problems that have been challenging for traditional medicinal chemistry approaches."

The Nature Reviews Drug Discovery article examines the prevalence of covalent drugs, safety considerations, mechanistic and pharmacological features, and approaches to design and optimization of targeted covalent inhibitors. Key points include:

  • Covalent drugs have made a major positive impact on human health, and there are dozens of covalent drugs on the market worldwide including broadly used medicines such as aspirin, clopidogrel (Plavix), lansoprazole (Prevacid) and esomeprazole (Nexium).

  • Despite the many successful covalent drugs, principles for the rational design of these molecules have only recently emerged. A description of progress in the design of targeted covalent drugs with a focus on the Avila strategy is discussed.

  • Several rationally designed, targeted covalent inhibitors have recently advanced in clinical development (neratinib, afatinib, PCI-32765 and the Avlia clinical candidate, AVL-292).

  • New publications have reported on targeted covalent inhibitors to diverse drug targets where each demonstrates high specificity of covalent bond formation to its respective target.

  • The pharmacological advantages of covalent drugs are discussed including the potential to address the problem of drug-resistance mutations that often arise in cancer and in infectious diseases.

Based on this review article, it is apparent that structural bioinformatics approaches, coupled with structure-based drug design, may enable the engineering of highly selective covalent drugs and a resurgence of interest in this important class of therapeutics.


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Related biology news :

1. IEEE-USA workshop to explore the challenges and opportunities of electric vehicle technology
2. New oyster farming technique increases productivity, offers entrepreneurial opportunities
3. IBIA Statement Regarding the Release of the National Research Council Report - Biometric Recognition: Challenges and Opportunities
4. Behind the secrets of silk lie high-tech opportunities
5. New book describes career opportunities in clinical research and how to qualify for them
6. Conference to discuss sensing technology developments and opportunities
7. Male antelopes trick females into extra sex opportunities
8. George Daley to discuss challenges and opportunities facing stem cell scientists
9. Synthetic biology offers new opportunities for interdisciplinary collaboration
10. NIGMS invests in scientific Grand Opportunities with Recovery Act funds
11. Frost & Sullivan Looks at Biometrics Advancement in Civil Security: Exploring Opportunities for Today and Beyond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Lemonade Stand Foundation (ALSF), a leading national childhood cancer ... bioinformatics lab, using ,big data, to advance the pace ... Liz Scott , co-executive director of ALSF and Alex,s ... Washington, D.C. , hosted by Vice President ... pediatric cancer research and awareness. The ...
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
Breaking Biology Technology: